Key takeaways for Virginia
- • GLP-1 RAs and GLP-1/GIP agonists are first-line injectables after metformin in 2025 ADA guidelines.
- • HbA1c reductions of 1.0-2.0 points are typical at maintenance dose.
- • Semaglutide and tirzepatide have proven cardiovascular benefits in T2D.
- • Cardinal Care (formerly Medallion + CCC Plus) coverage rules apply for Type 2 Diabetes patients in Virginia — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Type 2 Diabetes
GLP-1 receptor agonists lower HbA1c by 1.0-2.0 percentage points on average, promote weight loss, and carry cardiovascular benefits validated in dedicated outcomes trials. Evidence grade: A (level 1, multiple RCTs and meta-analyses). The ADA Standards of Care 2025 list GLP-1 RAs (or GLP-1/GIP dual agonists like tirzepatide) as preferred when glycemic, weight, or CV/renal goals are not met on metformin. Always paired with diet, activity, and ongoing labs — not standalone therapy.
Virginia-specific context
Virginia has telehealth access concentrated in Virginia Beach, Norfolk, Chesapeake metros, with additional reach to Richmond and Arlington. VCU Health, Inova Health System, Sentara Healthcare is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.vdh.virginia.gov.
Virginiatelehealth & pricing rules
- • Virginia permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Virginia allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Virginia: ~$269/mo (compounded options often lower, brand higher).